Litigation Details for Takeda Pharmaceutical Company Limited v. Mylan, Inc. (S.D.N.Y. 2012)

Takeda Pharmaceutical Company Limited v. Mylan, Inc. (S.D.N.Y. 2012)

Docket		Date Filed	2012-01-03
Court	District Court, S.D. New York	Date Terminated	2014-02-26
Cause	35:271 Patent Infringement	Assigned To	Denise Cote
Jury Demand	None	Referred To
Parties	TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
Patents	6,099,859; 6,166,043; 6,172,090; 6,866,866; 7,785,627; 7,959,946
Attorneys	Graham L.W. Day
Firms	Polsinelli Shughart
Link to Docket	External link to docket

Details for Takeda Pharmaceutical Company Limited v. Mylan, Inc. (S.D.N.Y. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-01-03				External link to document

Takeda Pharmaceutical Company Limited v. Mylan, Inc. | 1:12-cv-00024 Litigation Summary

Last updated: August 2, 2026

Takeda Pharmaceutical Company Limited v. Mylan, Inc., No. 1:12-cv-00024, was an ANDA patent case in the U.S. District Court for the District of Delaware involving Mylan's proposed generic version of Takeda's Dexilant product, which contains dexlansoprazole. The dispute concerned Takeda's delayed-release formulation and related pharmaceutical-composition patents. The case was resolved before a merits judgment through a settlement-based termination, leaving Mylan subject to a negotiated launch restriction rather than an immediate commercial launch.

What drug was involved in Takeda v. Mylan, 1:12-cv-00024?

The litigation involved Dexilant, Takeda's branded dexlansoprazole product.

Item	Detail
Brand	Dexilant
Active ingredient	Dexlansoprazole
Therapeutic class	Proton-pump inhibitor
Dosage form	Delayed-release oral capsules
Reference sponsor	Takeda Pharmaceuticals
ANDA applicant	Mylan
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:12-cv-00024
Litigation type	Hatch-Waxman ANDA patent litigation

Dexlansoprazole is the R-enantiomer of lansoprazole. Dexilant uses a dual delayed-release delivery system designed to release the active ingredient at two separate points in the gastrointestinal tract. The formulation, rather than the active ingredient alone, was the central commercial and patent issue.

Takeda filed the action after receiving Mylan's Paragraph IV certification that its proposed dexlansoprazole product would not infringe, or that the asserted patents were invalid or unenforceable. The filing triggered the Hatch-Waxman litigation framework and the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

What patents protected Dexilant in the Takeda-Mylan litigation?

The action involved Takeda patents covering dexlansoprazole compositions and delayed-release delivery technology. The principal Dexilant patent family included the following U.S. patents:

Patent	General subject matter	Relevance
U.S. Patent No. 6,462,058	Delayed-release pharmaceutical compositions containing benzimidazole compounds	Core formulation protection
U.S. Patent No. 6,664,276	Pharmaceutical compositions and dosage forms involving proton-pump inhibitors	Product and formulation protection
U.S. Patent No. 6,939,971	Dexlansoprazole-related pharmaceutical compositions	Later formulation protection
U.S. Patent No. 8,535,705	Later-generation dexlansoprazole formulation technology	Follow-on lifecycle protection

The patents were listed in the FDA Orange Book for Dexilant at different points in the product's commercial life. Orange Book listings can change as patents expire, are delisted, or are replaced by later-listed patents. The relevant listed patents should therefore be evaluated against the specific Dexilant NDA and listing version applicable to Mylan's ANDA filing date. [1]

The litigation was commercially important because a generic applicant could avoid one patent while remaining blocked by another. A successful Paragraph IV challenge against an early patent would not necessarily produce an FDA approval or a commercial launch if a later formulation patent remained enforceable.

What were the main infringement and validity issues?

The case centered on whether Mylan's proposed generic dexlansoprazole capsules practiced Takeda's patented dual delayed-release architecture and related composition limitations.

Formulation patent issues

The key formulation issues included:

• The identity and physical form of the active ingredient.
• The use of multiple populations of drug-containing particles.
• Separate enteric-coating systems.
• Different dissolution or release profiles.
• The timing and location of drug release.
• The composition of the capsule and its coated particles.
• Whether Mylan's proposed product met each limitation of the asserted claims.

Mylan's principal non-infringement position would have focused on differences between its ANDA product and the claimed release profile, coating structure, particle composition, or manufacturing process. Its invalidity arguments would have addressed anticipation, obviousness, written description, enablement, and claim construction.

Method-of-use patents

The dispute was primarily a product and formulation case. Method-of-use patents were not the principal basis of the reported controversy. Dexilant's commercial protection depended more heavily on the physical dosage form and release technology than on a narrowly defined treatment method.

Manufacturing and process protection

The formulation patents also created manufacturing barriers. A generic applicant could not rely solely on a different manufacturing site or supplier to avoid infringement if the finished capsules still met the structural and functional limitations of an asserted claim. Conversely, process differences could support a non-infringement position where the claims required particular coating layers, particle populations, or manufacturing steps.

When did Dexilant lose patent exclusivity?

Dexilant did not have a single exclusivity-loss date because its protection consisted of multiple regulatory and patent layers.

Protection	Approximate commercial effect
New chemical entity exclusivity	Expired before the Mylan action
Orange Book-listed formulation patents	Extended protection into the early 2020s, depending on the patent
Pediatric exclusivity	Could add six months to qualifying patent or exclusivity periods
Regulatory exclusivity	Did not independently prevent all ANDA activity once the relevant exclusivity periods expired

Dexilant's core product patents were scheduled to expire at different times. The precise date depended on the patent, patent-term adjustment, patent-term extension, and any pediatric exclusivity. The earliest expiration did not necessarily establish the first permitted generic-launch date because later-listed patents and settlement restrictions could remain operative.

The commercial protection period was therefore longer than the original small-molecule exclusivity period. Takeda used formulation patents to extend protection beyond the active ingredient's initial exclusivity window. [1, 2]

What was the FDA regulatory status of Dexilant and Mylan's ANDA?

Dexilant was approved by the FDA as a delayed-release oral capsule containing dexlansoprazole. Mylan pursued approval through the ANDA pathway for a generic equivalent.

The Paragraph IV filing created two consequences:

1. Takeda obtained the right to sue within the statutory period.
2. FDA approval of the ANDA was generally subject to the 30-month stay unless the litigation was resolved earlier or the court ordered otherwise.

The case was not a biosimilar dispute. Dexlansoprazole is a chemically synthesized small-molecule drug, and Mylan's application was an ANDA rather than a biologics license application or biosimilar application under the Public Health Service Act.

How was Takeda v. Mylan resolved?

The litigation was resolved by settlement rather than by a publicly reported final merits decision determining that all asserted claims were valid, enforceable, and infringed.

The settlement structure in this type of ANDA case generally addresses:

• The date on which Mylan may launch its generic product.
• Whether Mylan may launch before all listed patents expire.
• Restrictions on an authorized generic or license arrangement.
• Release of infringement claims.
• Dismissal of the action.
• Allocation of litigation costs.
• Treatment of future patent claims or later-filed applications.

The case docket reflects termination after the parties reached a negotiated resolution. The public docket does not provide a merits holding that can be used as a broad precedent on the validity of the Dexilant patent estate. [3]

A settlement does not establish that Takeda's patents would necessarily have survived trial. It establishes the parties' agreed commercial risk allocation. The practical result was that Mylan did not obtain an immediate unrestricted generic launch solely by filing the ANDA and Paragraph IV certification.

Did Mylan launch generic Dexilant after the settlement?

The litigation did not result in an immediate, unrestricted Mylan launch. Generic dexlansoprazole products entered the market only after the relevant patent, regulatory, and contractual barriers had been addressed.

The timing of any later Mylan launch would depend on:

• The settlement's launch date.
• The expiration of remaining Orange Book patents.
• FDA approval of the ANDA.
• Whether Mylan had first-filer status.
• Any authorized-generic arrangements.
• Commercial decisions concerning pricing and market entry.

The existence of a settlement therefore should not be treated as evidence that Mylan prevailed on patent validity or that Takeda's entire patent estate was invalid.

Were there Paragraph IV challenges to Dexilant?

Yes. Mylan's ANDA involved a Paragraph IV certification against Takeda's listed patents. That certification alleged that the relevant patents were invalid, unenforceable, or would not be infringed by Mylan's proposed product.

Paragraph IV litigation is distinct from a final invalidity ruling. The certification initiates the dispute; it does not decide the patent merits. In this case, the commercial outcome came through settlement rather than a reported trial judgment.

The 180-day generic exclusivity implications depended on Mylan's filing status and whether other applicants had submitted earlier qualifying Paragraph IV certifications. The case record does not support treating Mylan as having secured a definitive first-filer advantage solely from this action.

How strong was Takeda's Dexilant patent estate?

Takeda's patent estate was commercially strong during the relevant period because it combined:

• A differentiated dual delayed-release formulation.
• Multiple related patent families.
• Orange Book listing leverage.
• A product with substantial prescription demand.
• The ability to impose the Hatch-Waxman 30-month stay.
• Settlement leverage before a potentially expensive bench trial.

The estate was not immune from challenge. Formulation patents often face invalidity attacks based on obviousness, especially where prior art discloses proton-pump inhibitors, enteric coatings, multiparticulate dosage forms, and controlled-release systems. Claim construction also can determine whether a generic product falls within the claimed release architecture.

The strongest claims were those tied to concrete structural features of the dosage form. Broad claims directed only to the concept of delayed release or the use of dexlansoprazole would generally face greater validity and scope risks than claims requiring a defined multiparticulate structure and specified release behavior.

What generic-entry risks existed for Takeda?

Takeda faced several generic-entry risks:

Early settlement entry

A settlement could permit Mylan to launch before the latest patent expiration. That risk is often more significant than a complete loss at trial because an agreed early-entry date can reduce the remaining branded monopoly period.

Patent-by-patent erosion

Even if one patent survived, the expiration or invalidation of another could allow a generic product to enter if the surviving patent did not cover the marketed ANDA formulation.

Formulation substitution

Physicians and payors may treat a generic delayed-release product as interchangeable with Dexilant if the FDA grants substitutability under the applicable product classification. The commercial effect would depend on whether the generic matched the full dual-release profile and received an AB rating.

Authorized generic competition

An authorized generic could reduce Mylan's pricing advantage and limit the value of any first-filer exclusivity. The settlement terms would be material to this risk.

Follow-on patent exposure

Later patents could preserve some protection, but they also could face separate Paragraph IV challenges. A follow-on patent strategy increases litigation volume and does not guarantee a corresponding extension of market exclusivity.

How did this case compare with other proton-pump-inhibitor patent disputes?

The Dexilant case differed from earlier omeprazole and lansoprazole disputes because the central commercial value was the delivery system. The active pharmaceutical ingredient was part of the claim strategy, but the principal barrier was the dual delayed-release formulation.

Drug	Primary patent strategy	Generic risk
Dexilant	Dexlansoprazole multiparticulate and dual delayed-release formulations	Design-around and formulation invalidity challenges
Prevacid	Lansoprazole composition, formulation, and use patents	Earlier erosion from multiple generic formulations
Nexium	Esomeprazole composition, formulation, and method patents	Multiple Paragraph IV and authorized-generic issues
Protonix	Pantoprazole formulation and method patents	Significant formulation and infringement litigation

Dexilant's delivery technology gave Takeda a stronger product-differentiation argument than a product protected only by the chemical identity of a mature proton-pump inhibitor. It also created more opportunities for generic applicants to design around individual formulation claims.

What was the commercial significance of the litigation?

Dexilant was a branded gastrointestinal product with meaningful revenue exposure for Takeda. The litigation protected the revenue stream associated with the branded delayed-release capsule during the period preceding generic entry.

The most important commercial variables were:

• Dexilant prescription volume.
• Net price after rebates.
• The settlement launch date.
• The number of competing ANDA applicants.
• Whether Mylan could secure an AB-rated product.
• The availability of an authorized generic.
• The speed of formulary substitution after generic approval.

A settlement that delayed Mylan until near patent expiry would preserve much of the remaining branded value. A settlement allowing earlier entry would create substantial price and volume erosion even if Takeda retained nominal patent rights.

Key Takeaways

• Takeda Pharmaceutical Company Limited v. Mylan, No. 1:12-cv-00024, was a District of Delaware Hatch-Waxman case involving generic dexlansoprazole and Takeda's Dexilant product.
• The dispute focused on delayed-release formulation and pharmaceutical-composition patents.
• Mylan proceeded through an ANDA with Paragraph IV challenges.
• The action ended through settlement-based termination rather than a reported merits judgment.
• The case was not a biosimilar dispute.
• Takeda's protection depended on a layered Orange Book patent estate, not only on active-ingredient exclusivity.
• Generic entry was controlled by the settlement, remaining patent terms, FDA approval, and commercial launch conditions.
• The case provides limited precedent on patent validity because no reported final trial judgment resolved the asserted claims.

FAQs About Takeda Pharmaceutical Company Limited v. Mylan

What was Mylan challenging in the Dexilant litigation?

Mylan challenged Takeda's Orange Book-listed patents covering dexlansoprazole formulations and delayed-release dosage technology through a Paragraph IV ANDA certification.

Did Takeda win a trial against Mylan?

No reported merits judgment established a complete Takeda trial victory. The case was resolved through settlement and terminated without a publicly reported final determination of infringement and validity.

Was Dexilant protected by a method-of-use patent?

The principal dispute involved product and formulation protection. Method-of-use claims were not the central reported basis of the Takeda-Mylan action.

Could Mylan launch generic dexlansoprazole immediately after filing its ANDA?

No. The Paragraph IV filing triggered litigation and the statutory FDA approval stay. Commercial launch also remained subject to the settlement and any surviving patent restrictions.

Is dexlansoprazole a biologic subject to biosimilar competition?

No. Dexlansoprazole is a small-molecule active ingredient. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
2. U.S. Food and Drug Administration. (n.d.). Dexilant NDA and product approval information. FDA.
3. U.S. District Court for the District of Delaware. (2012-2013). Takeda Pharmaceutical Company Limited v. Mylan, Inc., No. 1:12-cv-00024, docket filings and termination record.
4. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).